PBYI Puma Biotechnology Inc

40.25
+2.9  (7.76%)
Previous Close 37.35
Open 37.25
Price To book 13.32
Market Cap 1.48B
Shares 36,818,000
Volume 1,377,113
Short Ratio 7.47
Av. Daily Volume 698,740

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Note this trial is conducted by competitor Roche (RHHBY), NOT by Puma. The event is likely to have a significant impact on the share price of Puma (e.g. positive data would likely have a negative impact on Puma and vice versa). Data are due 1Q 2017.
Roche (RHHBY) - Perjeta + Herceptin (APHINITY)
Adjuvant HER2+ breast cancer
Phase 2 data due 1H 2017.
Neratinib
HER2-positive metastatic breast cancer patients with brain metastases
Phase 3 planned
Neratinib plus temsirolimus
Fourth line HER2-positive metastatic breast cancer
Phase 2 biomarker data released December 7, 2016.
PB272 (NSABP FB-7)
Neoadjuvant treatment for patients with HER2-positive breast cancer
Phase 2 preliminary data released December 8, 2016. Further data due 2Q 2017.
Neratinib SUMMIT
HER2 non-amplified breast cancer that has a HER2 mutation
Phase 2 additional data released December 8 2016. Noted high rates of diarrhea. Further data due 2Q 2017.
Neratinib monotherapy with high dose loperamide prophylaxis - CONTROL
Extended adjuvant treatment of early stage HER2-positive breast cancer
Phase 3 data due 1H 2017.
Neratinib
Third-line HER2-positive metastatic breast cancer
Phase 2 completed.
Neratinib - NEfERTT trial
HER2-positive breast cancer first line
PDUFA date July 21, 2017.
PB272 ExteNET trial
Extended adjuvant HER2-positive early stage breast cancer

Latest News

  1. Puma Biotechnology to Present at RBC Capital Markets Healthcare Conference
  2. Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference
  3. Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?
  4. Puma (PBYI) Expands Study Cohort for Lead Candidate PB272
  5. Newman Ferrara LLP Announces Corporate Governance Investigation of Puma Biotechnology, Inc. - PBYI
  6. PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events
  7. Puma Biotechnology Expands Cohort in Phase II SUMMIT Trial of PB272 in HER2 Mutation-Positive Cancer Patients
  8. Puma Biotechnology Expands Cohort in Phase II SUMMIT Trial of PB272 in HER2 Mutation-Positive Cancer Patients
  9. PUMA BIOTECHNOLOGY, INC. Financials
  10. Puma Biotechnology to Present at J.P. Morgan Healthcare Conference
  11. Puma Biotechnology to Move Stock Exchange Listing to Nasdaq
  12. PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or St
  13. Puma Biotechnology to Move Stock Exchange Listing to Nasdaq
  14. Puma Cancer Drug Suffers 'Approvability Risk' On Extreme Side Effect
  15. PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events
  16. Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2016 San Antonio Breast Cancer Symposium
  17. Puma Biotechnology Presents Results of Biomarker Analysis of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer at the 2016 San Antonio Breast Cancer Symposium
  18. Puma Biotechnology Presents Interim Results of Phase II Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2016 San Antonio Breast Cancer Symposium
  19. Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA Registration Standards
  20. CORRECTING and REPLACING Puma Biotechnology Initiates a Managed Access Program for PB272 (Neratinib) Outside the United States